Summary of minutes of EUCAST Steering Committee Meeting  
Vienna, Austria, 15-16 February 2011

**Attending**
- Dr Petra Apfalter (PA) EUCAST, Austria
- Dr Derek F.J. Brown (DB) Scientific Secretary, United Kingdom
- Dr Rafael Canton (RC) Clinical Data Co-ordinator, Spain
- Dr Christian Giske (CG) SRGA, Sweden
- Dr Marina Ivanova (MI) EUCAST, Estonia
- Prof Gunnar Kahlmeter (GK) Chairperson, Sweden
- Prof Alasdair P. MacGowan (AM) BSAC, United Kingdom
- Dr Johan W. Mouton (JM) CRG, The Netherlands
- Prof Arne Rodloff (AR) DIN, Germany
- Prof Claude-James Soussy (CS) CA-SFM, France
- Dr Martin Steinbakk (MS) NWGA, Norway

**Present for item 21 and 22**
- Dr Robert Skov, State Serum Institute, Denmark

<table>
<thead>
<tr>
<th></th>
<th>Chairman’s welcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Minutes of meeting of 22-23 November 2010</td>
</tr>
<tr>
<td>3</td>
<td>Matters arising from minutes of 22-23 Nov 2010 (items not covered by agenda)</td>
</tr>
<tr>
<td></td>
<td>MIC distributions for <em>C. difficile</em> will be added to the MIC database.</td>
</tr>
<tr>
<td></td>
<td>Approaches to dealing with the effects of changing breakpoints on resistance surveillance have been sent to ECDC.</td>
</tr>
<tr>
<td></td>
<td>Cefotaxime, cefuroxime, ceftazidime, benzylpenicillin, phenoxymethylpenicillin, piperacillin-tazobactam and amoxicillin documents have been released.</td>
</tr>
<tr>
<td></td>
<td>ECOFFs have been defined for Enterobacteriaceae.</td>
</tr>
<tr>
<td>4</td>
<td>New agents</td>
</tr>
<tr>
<td>5</td>
<td>Status of EUCAST rationale documents</td>
</tr>
<tr>
<td>6</td>
<td>Breakpoint issues</td>
</tr>
<tr>
<td>7</td>
<td>Expert rules subcommittee</td>
</tr>
<tr>
<td>8</td>
<td>Antifungal susceptibility testing subcommittee</td>
</tr>
<tr>
<td>9</td>
<td>Anaerobe subcommittee</td>
</tr>
<tr>
<td>10</td>
<td>Organisms without EUCAST breakpoints</td>
</tr>
<tr>
<td></td>
<td>Proposed breakpoints for <em>H. pylori</em>, with notes, will be released for consultation with all groups.</td>
</tr>
<tr>
<td></td>
<td>ECOFFs for <em>C. difficile</em> will be released.</td>
</tr>
</tbody>
</table>
The status of breakpoints and current projects for several other groups was reviewed.

11 **ECCMID Milan 8-10 May, 2011** There will be several EUCAST sessions.

12 **EMA** EUCAST comments on the draft document “Guideline on the Evaluation of Medicinal Products indicated for Treatment of Bacterial Infections” will be sent to EMA.

13 **CLSI** GK and DB reported on several useful sessions at the January 2011 meeting in Orlando.

14 **ECDC** The next tender period will run from September 2011. There will be changes to the grant periods to bring the funding periods into line with ECDC funding streams.

15 **Implementation of EUCAST breakpoints** GK and DB presented maps showing implementation of NACs, EUCAST breakpoints and EUCAST disk diffusion in Europe. There has been rapid progress in implementation.

Manufacturers’ readiness for EUCAST breakpoints and methods continues to be an issue with some details but there is constant progress.

Breakpoint tables continue to be developed and extended.

*Moraxella catarrhalis* breakpoints will be released for general consultation.

Noted that a *N. gonorrhoeae* QC control strain is needed.

16 **EUCAST statutes** An updated version will be presented for ratification at the General Committee meeting at ECCMID.

17 **Website** The frequently asked questions section continues to be expanded. An errata section has been added to cover typographical errors to be corrected in the next version. A section listing changes to the website has been added to the homepage and there is a section giving previous versions of tables. A note on update of documents was approved.

18 **Co-amoxiclav breakpoints and susceptibility testing** Discussions continue on the most appropriate fixed concentration of clavulanate.

19 **Cefixime and N. gonorrhoeae** Propose reduction of the breakpoints to 0.06/0.06 mg/L will be sent this to national committees for consultation.

20 **Trimethoprim-sulfametrol** Susceptibility of all trimethoprim-sulfonamide combinations can be inferred from the trimethoprim-sulfamethoxazole susceptibility.

21 **Ciprofloxacin breakpoints for Salmonella spp.** Separate breakpoint will be provided.

22 **Testing S. aureus for β-lactamase production** Use of sharp edge/cloverleaf tests were discussed following a presentation by RS.

23 **Detection of β-lactam resistance in H. influenzae** Detection of β-lactam resistance in *H. influenzae* was discussed.

24 **Beta-lactamase inhibitor combination** There was a preliminary presentation from a manufacturer.

25 **Any other business** None.

26 **Next meetings**

- 10-11 May 2011, Milan, Italy (after ECCMID).

Ratified summary of minutes of meeting 15-16 February 2011. Prepared by DB, GK and RC